Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ruoshuang Han"'
Autor:
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-23 (2024)
Abstract Background Osimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients whereas drug resistance remains inevitable. Now we recognize that the interactions between the t
Externí odkaz:
https://doaj.org/article/aa4d438b2d26449785cbb6e7670dc714
Autor:
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b4216edbde114af99a0b2210e96fa4da
Autor:
Sangtian Liu, Fengying Wu, Xuefei Li, Chao Zhao, Yijun Jia, Keyi Jia, Ruoshuang Han, Meng Qiao, Wei Li, Jia Yu, Fei Zhou, Anwen Xiong, Bin Chen, Jue Fan, Shengxiang Ren, Caicun Zhou
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDespite disappointing outcomes from immuno-monotherapy, studies reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy. Whether the response to prior EGFR-TKI has association with the outcomes of su
Externí odkaz:
https://doaj.org/article/2fb55bf23ccc404ba3815d788e9e1a46
Autor:
Donglai Chen, Xiaofan Wang, Fuquan Zhang, Ruoshuang Han, Qifeng Ding, Xuejun Xu, Jian Shu, Fei Ye, Li Shi, Yiming Mao, Yongbing Chen, Chang Chen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The benefit of adjuvant chemotherapy (ACT) remains unknown for patients with stage I lung adenocarcinoma (ADC) with spread through air spaces (STAS). This study investigated the effect of adjuvant chemotherapy in stage I ADC/STAS-positive
Externí odkaz:
https://doaj.org/article/ebe9a77d4b5e410da49c506e6d45095c
Autor:
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Haowei Wang, Sha Zhao, Yijun Jia, Xiaozhen Liu, Jiayu Li, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
Publikováno v:
European Journal of Cancer.
Autor:
Chao Zhao, Sangtian Liu, Xiaozhen Liu, Sha Zhao, Yiwei Liu, Ruoshuang Han, Yijun Jia, Qian Zhang, Donglai Chen, Xuefei Li, Jinpeng Shi, Caicun Zhou, Jiayu Li
Publikováno v:
Transl Lung Cancer Res
Background Resistance is almost inevitable and is still a major obstacle in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Only limited relevant clinical studies evaluated the therapeutic effects by combing metformin
Autor:
Tao Jiang, Fei Zhou, Wei Li, Sangtian Liu, Guanghui Gao, Jiayu Li, Meng Qiao, Yiwei Liu, Yayi He, Caicun Zhou, Sha Zhao, Chao Zhao, Anwen Xiong, Zhiyu Liu, Shengxiang Ren, Xuefei Li, Chunxia Su, Ruoshuang Han, Yijun Jia
Publikováno v:
Transl Lung Cancer Res
Background A strong association between M descriptors and prognosis of non-small cell lung cancer (NSCLC) has been demonstrated recently. However, its predictive and prognostic significance for advanced NSCLC patients treated with immune checkpoint i
Autor:
Xuefei Li, He Du, Yayi He, Guanghui Gao, Zhemin Zhang, Qi Wang, Ruoshuang Han, Fengying Wu, Xiaoxia Chen, Caicun Zhou, Xiaomin Cheng, Jiayu Li, Shengxiang Ren, Chao Zhao, Jinpeng Shi, Chunxia Su
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy has boosted the prognosis in advanced lung cancer. Meanwhile, accumulating cases showed the correlation between tuberculosis (TB) reactivation and an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe487066ac9d51e4a95623466bcd0240
https://europepmc.org/articles/PMC8577979/
https://europepmc.org/articles/PMC8577979/
Autor:
Xuefei Li, Jiawei Luo, Jinpeng Shi, Yijun Jia, Meng Qiao, Sangtian Liu, Sha Zhao, Ruoshuang Han, Xiaozhen Liu, Chao Zhao, Chunxia Su, Shengxiang Ren, Caicun Zhou, Tao Jiang, Limin Zhang
Publikováno v:
International Journal of Cancer. 145:1432-1444
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-1/PD-L1) pathway have profoundly improved the clinical management of non-small-cell lung cancer (NSCLC). Nevertheless, the superiority of single-agent PD-1/PD-L1 i
Autor:
Fengying Wu, Meng Qiao, Keyi Jia, Bin Chen, Anwen Xiong, Sangtian Liu, Yijun Jia, Wei Li, Caicun Zhou, Chao Zhao, Fei Zhou, Shengxiang Ren, Xuefei Li, Jue Fan, Ruoshuang Han, Jia Yu
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundDespite disappointing outcomes from immuno-monotherapy, studies reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy. Whether the response to prior EGFR-TKI has association with the outcomes of su